Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions

被引：0
|
作者：
Tu, Hai-Yan
Kai Yin
Ke, E-E
Wu, Si-Pei
Zhao, Xiaotian
Li, Yang-Si
Zheng, Mei-Mei
Liu, Si-Yang Maggie
Sun, Yue-Li
Lin, Jia-Xin
Bai, Xiao-Yan
Zhang, Yi-Chen
Qing Zhou
Yang, Jin-Ji
Zhong, Wenzhao
Wang, Bin-Chao
Zhu, Dongqin
Yang, Lingling
Ou, Qiuxiang
Wu, Yi-Long
机构：
[1] South China Univ Technol, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp,Sch Med, Guangzhou, Peoples R China
[2] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Sch Clinical Med 2, Guangzhou, Peoples R China
[3] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[4] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China
[5] Nanjing Geneseeq Technol Inc, Geneseeq Res Inst, Nanjing, Peoples R China
[6] Jinan Univ Chinese, Dept Hematol, Sch Med, Affiliated Hosp 1,Inst Hematol,Key Lab Regenerati, Jinan, Peoples R China
[7] Chinese Thorac Oncol Grp CTONG, Guangzhou, Peoples R China
[8] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[9] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[10] Guangdong Prov Peoples Hosp, Dept Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2591
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation
    Zhao, Ruiying
    Li, Jiaqi
    Guo, Lianying
    Xiang, Chan
    Chen, Shengnan
    Zhao, Jikai
    Shao, Jinchen
    Zhu, Lei
    Ye, Min
    Qin, Gang
    Chu, Tianqing
    Han, Yuchen
    TARGETED ONCOLOGY, 2024, 19 (02) : 277 - 288
  • [42] EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation
    Ruiying Zhao
    Jiaqi Li
    Lianying Guo
    Chan Xiang
    Shengnan Chen
    Jikai Zhao
    Jinchen Shao
    Lei Zhu
    Min Ye
    Gang Qin
    Tianqing Chu
    Yuchen Han
    Targeted Oncology, 2024, 19 : 277 - 288
  • [43] Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer
    Wei, Xue-Wu
    Gao, Xin
    Zhang, Xu-Chao
    Yang, Jin-Ji
    Chen, Zhi-Hong
    Wu, Yi-Long
    Zhou, Qing
    THORACIC CANCER, 2020, 11 (06) : 1512 - 1521
  • [44] Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
    Metro, Giulio
    Baglivo, Sara
    Bellezza, Guido
    Mandarano, Martina
    Gili, Alessio
    Marchetti, Giovanni
    Toraldo, Marco
    Molica, Carmen
    Reda, Maria Sole
    Tofanetti, Francesca Romana
    Siggillino, Annamaria
    Prosperi, Enrico
    Giglietti, Antonella
    Di Girolamo, Bruna
    Garaffa, Miriam
    Marasciulo, Francesca
    Minotti, Vincenzo
    Gunnellini, Marco
    Guida, Annalisa
    Sassi, Monica
    Sidoni, Angelo
    Roila, Fausto
    Ludovini, Vienna
    GENES, 2021, 12 (05)
  • [45] Characterization of ERBB2 alterations in non-small cell lung cancer.
    Singh, Vijendra
    Feldman, Rebecca
    Sukari, Ammar
    Kim, Chul
    Mamdani, Hirva
    Spira, Alexander, I
    Bepler, Gerold
    Kim, Edward S.
    Raez, Luis E.
    Pai, Sachin Gopalkrishna
    Ikpeazu, Chukwuemeka
    Vanderwalde, Ari M.
    Xiu, Joanne
    Wozniak, Antoinette J.
    Borghaei, Hossein
    Liu, Stephen, V
    Nagasaka, Misako
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] ERBB2 AND ERBB3 EXPRESSION IN RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS)
    Freixinos, Victor
    Salcedo, Maite
    Tallada, Natalia
    Murtra-Garrell, Nuria
    Navarro, Alejandro
    Martinez, Pablo
    Cedres, Susana
    Teixido, Cristina
    Hernandez-Losa, Javier
    Lopez, Eva
    Montero, M. A.
    Peg, Vicente
    Pallisa, Esther
    Canela, Mercedes
    Felip, Enriqueta
    Ramon Y Cajal, Santiago
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1063 - S1064
  • [47] Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas
    Costa, Daniel B.
    Jorge, Susan E.
    Moran, Jason P.
    Freed, Jason A.
    Zerillo, Jessica A.
    Huberman, Mark S.
    Kobayashi, Susumu S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 918 - 923
  • [48] ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China
    Li, Hui
    Li, Xiang
    Lan, Shaowei
    Zuo, Xuerong
    Du, Tianying
    Liu, Ying
    Zhang, Caixia
    Zhu, Jing
    Cheng, Ying
    TUMORI JOURNAL, 2023, 109 (03): : 276 - 281
  • [49] EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients
    Bae, Nack Cheon
    Chae, Myung Hwa
    Lee, Myung Hoon
    Kim, Kyung Mee
    Lee, Eung Bae
    Kim, Chang Ho
    Park, Tae-In
    Han, Sung Beom
    Jheon, Sanghoon
    Jung, Tae Hoon
    Park, Jae Yong
    CANCER GENETICS AND CYTOGENETICS, 2007, 173 (02) : 107 - 113
  • [50] Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
    Piotrowska, Zofia
    Tan, Daniel Shao-Weng
    Smit, Egbert F.
    Spira, Alexander I.
    Soo, Ross A.
    Nguyen, Danny
    Lee, Victor Ho-Fun
    Yang, James Chih-Hsin
    Velcheti, Vamsidhar
    Wrangle, John M.
    Socinski, Mark A.
    Koczywas, Marianna
    Janik, John E.
    Jones, Jeffrey
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4218 - +
12345